银杏二萜内酯葡胺联合依达拉奉右莰醇、丁苯酞注射液 对超溶栓时间窗急性脑梗死的临床应用.

Objective: The purpose of this study was to explore the clinical application of diterpene ginkgolides meglumine combined with edaravone dextracanthol and butylphthalide injection in treating acute cerebral infarction with beyond thrombolytic time window. Methods: The clinical data of 120 patients with acute cerebral infarction with beyond thrombolytic time window admitted to the Department of Neurology in Affiliated Hospital of Jiangnan University were retrospectively analyzed, and the patients were divided into control group and study group. The control group (60 cases) was treated with edaravone dextracanthol and butylphthalide injection, and the study group (60 cases) was added with diterpene ginkgolides meglumine. The hemorheology indexes, the peripheral blood inflammatory factors, neurological function (NIHSS score), daily living ability (MBI score). Results: After 10 days of treatment, the hematocrit, plasma viscosity and whole blood high shear viscosity decreased in both groups, and the decrease in the study group was greater than that in the control group (P<0.05). The levels of IL-6, CRP and NSE in both groups were also the same as above. The scores of NIHSS decreased in both groups after treatment. The rate of good prognosis was the same between the two groups 10 days after treatment (P>0.05), but the rate of good prognosis in the study group was higher than that in the control group at the 30th day after treatment (P<0.05). Conclusion: Diterpene ginkgolides meglumine combined with edaravone dextracanthol and butylphthalide injection has a good effect in the treatment of acute cerebral infarction with beyond thrombolytic time window, and has fewer adverse reactions. [ABSTRACT FROM AUTHOR]